African American men have the highest rates of prostate cancer and the death rates due to prostate cancer are two times higher than Caucasians. The reason for the disparity is still unclear, but recent scientific studies suggest that the genetic and molecular changes in different ethnics are responsible for the disparity in African American men. These changes are responsible for different clinical outcome of prostate cancer in African American. Recent preliminary study showed that differences at molecular levels in prostate tissues between African American and Caucasian do exist. Therefore, we would like to further identify the molecules associated with prostate cancer racial disparity at the protein level using our novel Proteomic Pathway Array method, and to understand the mechanism of these molecules as a cause of the health disparity for prostate cancer among African American men. The success of the proposed study will have a profound benefit on the health of men, especially African Americans. The search for molecules that can distinguish those patients who will develop aggressive prostate cancer from those who will have a less aggressive course can help to identify patients who need more close surveillance and treatment. Furthermore, the identification and functional studies of molecules responsible for the aggressive behavior of prostate cancer in African American will help to design anti-cancer drugs and strategies. The translation from the discovery from this study to clinical application (diagnosis and treatment) can be achieved at a short period of time after completion of this study. The potential contributions ofthe study to advance health disparity research will be 1) identify biomarkers for prostate cancer racial disparity, 2) provide molecular bases why there is a racial difference in prostate cancer, 3) open a brand new way to look into the causes of racial difference in prostate cancer.

Public Health Relevance

This study will lead to discovery of novel signal transduction proteins involved in racial disparity of prostate cancer and will generate clinically relevant information for developing biomarkers for early detection of aggressive prostate cancer in the African American community. The functional study of these signal transduction proteins in the context of racial disparity may lead to development of novel treatment strategy for prostate cancer according to ethnic background.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA149556-03S1
Application #
8761333
Study Section
Special Emphasis Panel (ZRG1-OBT-A (50))
Program Officer
Banez, Lionel L
Project Start
2013-12-23
Project End
2015-12-22
Budget Start
2013-12-23
Budget End
2015-12-22
Support Year
3
Fiscal Year
2014
Total Cost
$246,200
Indirect Cost
$60,569
Name
New York University
Department
Pathology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Zhan, Yang; Zhang, Guanyi; Wang, Xiaojie et al. (2016) Interplay Between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediate Castration Resistance. Mol Cancer Res :
Daniels, Garrett; Zhang, Xinmin; Zhong, Xuelin et al. (2016) Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation. Oncotarget 7:39556-39571
Wu, Xinyu; Deng, Fangming; Li, Yirong et al. (2015) ACSL4 promotes prostate cancer growth, invasion and hormonal resistance. Oncotarget 6:44849-63
Liang, Jiaqian; Li, Xin; Li, Yirong et al. (2015) LEF1 targeting EMT in prostate cancer invasion is mediated by miR-181a. Am J Cancer Res 5:1124-32
Leach, Damien A; Need, Eleanor F; Toivanen, Roxanne et al. (2015) Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget 6:16135-50
Liang, Jiaqian; Li, Yirong; Daniels, Garrett et al. (2015) LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a. Mol Cancer Res 13:681-8
Daniels, Garrett; Jha, Ruchi; Shen, Ying et al. (2014) Androgen receptor coactivators that inhibit prostate cancer growth. Am J Clin Exp Urol 2:62-70
Daniels, Garrett; Li, Yirong; Gellert, Lan Lin et al. (2014) TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr Relat Cancer 21:127-42
Wu, Xinyu; Daniels, Garrett; Lee, Peng et al. (2014) Lipid metabolism in prostate cancer. Am J Clin Exp Urol 2:111-20
Singh, Mandeep; Jha, Ruchi; Melamed, Jonathan et al. (2014) Stromal androgen receptor in prostate development and cancer. Am J Pathol 184:2598-607

Showing the most recent 10 out of 16 publications